Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.

Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.

Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.

Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

SoftBank Vision Fund owns more than 40% of the precision cancer drug developer, which raised $400m approximately 18 months ago.

The 6 Dimensions Capital-backed cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

Gilead Sciences will invest $275m in return for a 49.9% stake as part of a deal that could see it purchase the cancer immunotherapy developer outright.